Brokers Set Expectations for NAMS Q3 Earnings

Key Points

• Analysts from HC Wainwright predict NewAmsterdam Pharma will report a Q3 2025 earnings per share of ($0.31), with a full-year consensus estimate of ($1.75) per share.
• Citigroup has raised its price target for NewAmsterdam Pharma from $42.00 to $50.00, maintaining a "buy" rating, while other analysts have issued various ratings, resulting in a consensus rating of "Moderate Buy".
• Institutional investors own approximately 89.89% of NewAmsterdam Pharma, with recent trading activity indicating increased holdings from several hedge funds.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) - Analysts at HC Wainwright issued their Q3 2025 earnings per share estimates for shares of NewAmsterdam Pharma in a research report issued on Monday, October 20th. HC Wainwright analyst J. Pantginis forecasts that the company will earn ($0.31) per share for the quarter. HC Wainwright has a "Buy" rating and a $52.00 price target on the stock. The consensus estimate for NewAmsterdam Pharma's current full-year earnings is ($1.75) per share. HC Wainwright also issued estimates for NewAmsterdam Pharma's Q4 2025 earnings at ($0.38) EPS, FY2025 earnings at ($1.33) EPS, FY2026 earnings at ($1.35) EPS, FY2027 earnings at $2.24 EPS, FY2028 earnings at $3.61 EPS and FY2029 earnings at $6.74 EPS.

Other research analysts have also issued reports about the company. Citigroup increased their price objective on NewAmsterdam Pharma from $42.00 to $50.00 and gave the company a "buy" rating in a research report on Friday. The Goldman Sachs Group began coverage on NewAmsterdam Pharma in a research report on Thursday, July 17th. They issued a "neutral" rating and a $27.00 price target on the stock. Royal Bank Of Canada raised their price target on NewAmsterdam Pharma from $38.00 to $39.00 and gave the stock an "outperform" rating in a research report on Thursday, August 7th. Wall Street Zen upgraded NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a research report on Saturday, July 5th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of NewAmsterdam Pharma in a research report on Wednesday, October 8th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, NewAmsterdam Pharma has a consensus rating of "Moderate Buy" and a consensus price target of $43.20.

NewAmsterdam Pharma Stock Performance

Shares of NAMS opened at $36.48 on Wednesday. The firm has a market capitalization of $4.11 billion, a price-to-earnings ratio of -22.52 and a beta of 0.02. The business's fifty day moving average price is $28.32 and its two-hundred day moving average price is $22.52. NewAmsterdam Pharma has a 52 week low of $14.06 and a 52 week high of $41.47.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.52) by $0.37. The business had revenue of $19.15 million for the quarter, compared to analyst estimates of $1.44 million. NewAmsterdam Pharma had a negative return on equity of 27.27% and a negative net margin of 259.07%.

Hedge Funds Weigh In On NewAmsterdam Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Frazier Life Sciences Management L.P. grew its holdings in NewAmsterdam Pharma by 3.0% during the second quarter. Frazier Life Sciences Management L.P. now owns 16,607,074 shares of the company's stock worth $300,754,000 after purchasing an additional 490,656 shares during the period. RA Capital Management L.P. grew its holdings in NewAmsterdam Pharma by 14.6% during the first quarter. RA Capital Management L.P. now owns 10,138,938 shares of the company's stock worth $207,544,000 after purchasing an additional 1,293,938 shares during the period. Wellington Management Group LLP grew its holdings in NewAmsterdam Pharma by 53.0% during the first quarter. Wellington Management Group LLP now owns 3,541,975 shares of the company's stock worth $72,504,000 after purchasing an additional 1,226,852 shares during the period. Adage Capital Partners GP L.L.C. grew its holdings in NewAmsterdam Pharma by 54.5% during the second quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company's stock worth $54,566,000 after purchasing an additional 1,062,359 shares during the period. Finally, Woodline Partners LP grew its holdings in NewAmsterdam Pharma by 0.5% during the first quarter. Woodline Partners LP now owns 2,442,397 shares of the company's stock worth $49,996,000 after purchasing an additional 11,615 shares during the period. Institutional investors own 89.89% of the company's stock.

Insider Buying and Selling

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 150,000 shares of NewAmsterdam Pharma stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $25.83, for a total value of $3,874,500.00. Following the sale, the chief accounting officer owned 15,000 shares of the company's stock, valued at $387,450. This trade represents a 90.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director James N. Topper purchased 1,260 shares of NewAmsterdam Pharma stock in a transaction that occurred on Monday, September 8th. The shares were bought at an average cost of $24.99 per share, with a total value of $31,487.40. Following the completion of the transaction, the director directly owned 3,027,864 shares of the company's stock, valued at approximately $75,666,321.36. The trade was a 0.04% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 2,391 shares of company stock valued at $58,424 and have sold 226,342 shares valued at $5,748,019. 20.84% of the stock is currently owned by company insiders.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.